SC
GENB

Stance Capital’s Generate Biomedicines GENB Stock Holding History

Stance Capital’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Buy
+1,384
New +$18.9K 0.01% 206

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Stance Capital's GENB Position: Q2 2026 in Review

Stance Capital opened a new position in Generate Biomedicines (GENB) in Q2 2026: 1,384 shares worth $23.3K. The stake represents 0.01% of the portfolio and ranks #206 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Stance Capital held 1,384 shares of Generate Biomedicines worth $23.3K as of Q2 2026.
  • Generate Biomedicines was a new Stance Capital position in Q2 2026.
  • Generate Biomedicines made up 0.01% of Stance Capital's portfolio in Q2 2026, its #206 holding.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.